IRIS
BRUERA, GEMMA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.380
EU - Europa 852
AS - Asia 763
SA - Sud America 133
AF - Africa 15
Totale 3.143
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.358
SG - Singapore 362
RU - Federazione Russa 198
IE - Irlanda 189
CN - Cina 147
BR - Brasile 108
DE - Germania 98
IT - Italia 85
VN - Vietnam 83
SE - Svezia 65
TR - Turchia 63
HK - Hong Kong 52
FI - Finlandia 47
FR - Francia 40
UA - Ucraina 39
GB - Regno Unito 35
CZ - Repubblica Ceca 21
IN - India 17
CA - Canada 10
AR - Argentina 8
BD - Bangladesh 8
ES - Italia 8
IQ - Iraq 7
PL - Polonia 7
MX - Messico 6
CL - Cile 5
DM - Dominica 4
ID - Indonesia 4
JP - Giappone 4
AT - Austria 3
LT - Lituania 3
PT - Portogallo 3
TN - Tunisia 3
VE - Venezuela 3
ZA - Sudafrica 3
BE - Belgio 2
BN - Brunei Darussalam 2
EC - Ecuador 2
MA - Marocco 2
NL - Olanda 2
PY - Paraguay 2
RO - Romania 2
SA - Arabia Saudita 2
TH - Thailandia 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
CO - Colombia 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
GF - Guiana Francese 1
GH - Ghana 1
GM - Gambi 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
KE - Kenya 1
LV - Lettonia 1
MD - Moldavia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PH - Filippine 1
PK - Pakistan 1
PS - Palestinian Territory 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TL - Timor Orientale 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.143
Salva come PNG Salva come JPEG
Città #
Chandler 216
Singapore 196
Dublin 189
Jacksonville 159
San Jose 122
Ashburn 113
Dallas 107
Santa Clara 56
Boardman 53
Hong Kong 51
Council Bluffs 50
New York 37
Beijing 32
The Dalles 32
Ho Chi Minh City 27
Izmir 26
Munich 26
Nanjing 26
Bremen 25
Lawrence 25
Princeton 25
Wilmington 22
Brno 21
Moscow 21
Helsinki 20
Hanoi 17
Columbus 15
São Paulo 15
Los Angeles 11
Nanchang 11
Pescara 11
San Mateo 11
Dong Ket 10
Lauterbourg 10
Rome 9
Turku 9
Ann Arbor 8
L’Aquila 8
Denver 7
Falkenstein 7
Hebei 7
Milan 7
Woodbridge 7
Lappeenranta 6
Orem 6
Warsaw 6
Chennai 5
Frankfurt am Main 5
Kunming 5
London 5
Tianjin 5
Toronto 5
Changsha 4
Des Moines 4
Roseau 4
San Francisco 4
Seattle 4
Tokyo 4
Ankara 3
Atlanta 3
Baghdad 3
Brooklyn 3
Campinas 3
Dearborn 3
Haiphong 3
Hefei 3
Jiaxing 3
L'aquila 3
Montreal 3
Mountain View 3
New Delhi 3
Philadelphia 3
Redwood City 3
Shenyang 3
Stockholm 3
Washington 3
Bandar Seri Begawan 2
Betim 2
Borås 2
Brasília 2
Brussels 2
Caracas 2
Chapecó 2
Duhok 2
Gramado 2
Guangzhou 2
Houston 2
Hải Dương 2
Jakarta 2
Jinan 2
Johannesburg 2
Lisburn 2
Macapá 2
Madrid 2
Monza 2
Ninh Bình 2
Norwalk 2
Paris 2
Phoenix 2
Pune 2
Totale 2.031
Salva come PNG Salva come JPEG
Nome #
The prevalent KRAS exon 2 c.35 G > A mutation in metastatic colorectal cancer patients: a biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens? 194
KRAS and Two Rare PI3KCA Mutations Coexisting in a Metastatic Colorectal Cancer Patient With Aggressive and Resistant Disease. 179
Real-life multidisciplinary treatment for unresectable colorectal cancer liver metastases including hepatic artery infusion with chemo-filtration and liquid biopsy precision oncotherapy: observational cohort study 164
Multidisciplinary Treatment, Including Locoregional Chemotherapy, for Merkel-Polyomavirus-Positive Merkel Cell Carcinomas: Perspectives for Patients Exhibiting Oncogenic Alternative Δ exon 6–7 TrkAIII Splicing of Neurotrophin Receptor Tropomyosin-Related Kinase A 155
Dose-finding study of oxaliplatin associated to capecitabine based preoperative chemoradiotherapy in locally advanced rectal cancer 154
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases 152
Multidisciplinary palliation for unresectable recurrent rectal cancer: Hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study 145
KRAS, NRAS and BRAF mutations detected by next generation sequencing, and differential clinical outcome in metastatic colorectal cancer (MCRC) patients treated with first line FIr-B/FOx adding bevacizumab (BEV) to triplet chemotherapy. 144
two simulteneous and very uncommom pi3kca mutations in a liver metastasis from colorectal cancer patient with aggressive and resistant disease 140
Dose-dense nonpegylated liposomal doxorubicin and docetaxel combination in breast cancer: Dose-finding study 137
Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). 127
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 121
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: An experience of multidisciplinary management in clinical practice 117
Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient WithKRASMutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy 110
Intensive first-line FIr-C/FOx-C association of triplet chemotherapy plus cetuximab in RAS wild-type metastatic colorectal cancer patients: preliminary phase II data and prediction of individual limiting toxicity syndromes by pharmacogenomic biomarkers. 109
Toxicity Syndromes, Patient-Related Clinical Indicator of Toxicity Burden Induced by Intensive Triplet Chemotherapy-Based Regimens in Gastrointestinal Cancers With Metastatic Disease 109
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 105
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab. 103
Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy. Evaluation of Masi G, Loupakis F, Salvatore L, et al. Bevaizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol 2010;11:845-52 103
Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments 103
Effectiveness and safety of intensive triplet chemotherapy plus bevecizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer 102
Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer 101
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice 100
Intensive multidisciplinary treatment strategies and patient resilience to challenge long-term survival in metastatic colorectal cancer: a case report in real life and clinical practice 97
Stravaso da antracicline: il punto di vista dell’oncologo. Caso clinico. 90
PSA as the driving biomarker to manage low- and intermediate-risk prostate cancer patients in clinical practice 69
Totale 3.230
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.262
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.262
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202116 0 0 0 0 0 0 0 0 0 0 0 16
2021/2022130 5 3 31 7 5 0 0 7 10 0 9 53
2022/2023579 27 42 2 79 55 67 2 32 244 0 12 17
2023/2024135 19 9 9 12 8 38 8 4 0 2 3 23
2024/2025632 35 12 43 38 86 46 99 53 131 15 54 20
2025/20261.112 63 107 73 103 132 95 168 34 95 183 50 9
Totale 3.230